Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 54

Sort by

Sort Order Select

Journal Articles

The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas

Nermin Kady, Suhaib Abdelrahman, Ahmar Rauf, Alyssa Burgess, Jonathan Weiss, Hirushi Gunasekara, Neal Thomas Ramseier, Ira P Maine, Alejandro Zevallos-Morales, Vanessa Perez-Silos, Ashley Wolfe, Alexandra Hristov, Noah A Brown, Kedar V Inamdar, Maria Sverdlov, Ying Samuel Hu, Carlos Murga-Zamalloa, Chenguang Wang, Ryan A Wilcox

Blood blood.2024025484.

https://doi.org/10.1182/blood.2024025484

Published: 2024

Includes: Multimedia, Supplemental data

Journal Articles

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Henry Dumke, Kellen Fitzpatrick, Tycel Phillips, Mark S Kaminski, Shannon A. Carty, Ryan A. Wilcox, Dahlia Sano, Malathi Kandarpa, Avery Polk, Benjamin L Viglianti, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6462.

https://doi.org/10.1182/blood-2024-203822

Published: 2024

Journal Articles

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Michael McLane, Victoria Nachar, Shannon A. Carty, Mark S Kaminski, Tycel J. Phillips, Dahlia Sano, Jonathan Weiss, Ryan A. Wilcox, Iman Ahmed, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 6348.

https://doi.org/10.1182/blood-2024-209170

Published: 2024

Journal Articles

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Blood (2024) 144 (Supplement 1): 982.

https://doi.org/10.1182/blood-2024-194242

Published: 2024

Journal Articles

Single Cell Atlas of Cutaneous T Cell Lymphomas Reveals XPO1 Dependency

Chenguang Wang, Ashley Wolfe, Xiangrong Geng, Ryan A. Wilcox

Blood (2024) 144 (Supplement 1): 858.

https://doi.org/10.1182/blood-2024-210072

Published: 2024

Journal Articles

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

Andrew L. Feldman, Guangzhen Hu, Surendra Dasari, Lisa M. Rimsza, David W. Scott, Jimena B. Gimenez, Farah M. Salama, Min Shi, Elías Campo, Wing Chung Chan, James R. Cook, Giorgio Inghirami, Elaine S. Jaffe, Ryan Morin, Phillipp W. Raess, Andreas Rosenwald, Kerry J. Savage, Louis M. Staudt, George W. Wright, Catalina Amador, Jan Delabie, Timothy C. Greiner, Javeed Iqbal, Laura K. Hilton, Sarah L. Ondrejka, German Ott, Stefania Pittaluga, Graham W. Slack, Susan L. Slager, Joo Y. Song, Hao-Wei Wang, Ahmed A. Aljudi, Stephen M. Ansell, Carlos Barrionuevo, James R. Cerhan, Jennifer R. Chapman-Fredricks, Weina Chen, Laurence de Leval, Alejandro A. Gru, David L. Jaye, Liuyan Jiang, Brad S. Kahl, Kennosuke Karube, Young Hyeh Ko, Eric Mou, Matthew J. Maurer, L. Jeffrey Medeiros, Roberto N. Miranda, Naoki Oishi, Perry M. Anamarija, Akira Satou, Xueju Wang, Ryan A. Wilcox, Xiaojun Wu, Tadashi Yoshino, Yu Zeng

Blood (2024) 144 (Supplement 1): 2974.

https://doi.org/10.1182/blood-2024-202410

Published: 2024

Journal Articles

CDK9 Is a Vulnerability in GATA-3 Driven and MCL-1 Independent T-Cell Lymphomas

Chenguang Wang, Suhaib Abdelrahman, Xiangrong Geng, Nermin Kady, Ira Maine, Ryan A. Wilcox

Blood (2024) 144 (Supplement 1): 233.

https://doi.org/10.1182/blood-2024-200199

Published: 2024

Journal Articles

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Blood (2024) 144 (Supplement 1): 1690.

https://doi.org/10.1182/blood-2024-211424

Published: 2024

Journal Articles

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Iman Ahmed, Victoria Nachar, Lydia Benitez, Shannon A. Carty, Dahlia Sano, Ryan A. Wilcox, XI Yang, Jonathan Weiss, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 3105.

https://doi.org/10.1182/blood-2024-205406

Published: 2024

Journal Articles

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

XI Yang, Iman Ahmed, Victoria Nachar, Shannon A. Carty, Ryan A. Wilcox, Jonathan Weiss, Dahlia Sano, Tycel J. Phillips, Yasmin H. Karimi

Blood (2024) 144 (Supplement 1): 4477.

https://doi.org/10.1182/blood-2024-211076

Published: 2024

Journal Articles

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

Blood (2023) 142 (Supplement 1): 847.

https://doi.org/10.1182/blood-2023-186969

Published: 2023

Journal Articles

GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition

Xiangrong Geng, Chenguang Wang, Thilini Perera, Badeia Saed, Ying Hu, Ashley Wolfe, John C Reneau, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2023-172509

Published: 2023

Journal Articles

Xpo-1 Antagonism Transcriptionally Reprograms and Is a Therapeutic Vulnerability in GATA-3 Driven T-Cell Lymphomas

Chenguang Wang, Nermin Kady, Ashley Wolfe, Ira Maine, Suhaib Abdelrahman, Vanessa Perez Silos, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2023-187231

Published: 2023

Journal Articles

Xpo-1 Antagonism Impairs CSF-1R Expression and Depletes Lymphoma-Associated Macrophages in T-Cell Lymphomas

Nermin Kady, Chenguang Wang, Ashley Wolfe, Ira Maine, Suhaib Abdelrahman, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2023-186364

Published: 2023

Journal Articles

Pre-Clinical Activity of Navitoclax in TCR-Driven and Non-ALCL Mature T-Cell Lymphomas

Xiangrong Geng, Chenguang Wang, Ashley Wolfe, Ira Maine, Suhaib Abdelrahman, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 4146.

https://doi.org/10.1182/blood-2023-174520

Published: 2023

Journal Articles

A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

Radhika Takiar, Wern Lynn Ng, Eshana Shah, Philip S. Boonstra, Yasmin H. Karimi, Shannon A. Carty, Ryan A. Wilcox, Carlos A. Murga Zamalloa, Grzegorz S. Nowakowski, Tycel J. Phillips

Blood (2022) 140 (Supplement 1): 9510–9511.

https://doi.org/10.1182/blood-2022-158825

Published: 2022

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Getting ALK inhibitors SHPshape

Ryan A. Wilcox

Blood (2022) 139 (5): 642–643.

https://doi.org/10.1182/blood.2021014301

Published: 2022

Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, Michael S. Khodadoust, Javier Munoz, Paul A. Hamlin, Youn H. Kim, Ryan A. Wilcox, Manish R. Patel, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 622.

https://doi.org/10.1182/blood-2021-148352

Published: 2021

Journal Articles

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Swami P. Iyer, MD, Auris Huen, MD, Bradley Haverkos, MD MPH, MS, Weiyun Z. Ai, Craig Okada, MD PhD, Timothy M. Kuzel, MD, Mary Jo Lechowicz, MD, Juan Pablo Alderuccio, MD, Ann Mohrbacher, MD, Don A. Stevens, MD, Ryan A. Wilcox, MD, Tatyana A. Feldman, MD, Suchitra Sundaram, MD, Deepa Jagadeesh, MDMPH, Nishitha Reddy, MD MSCI, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-136018

Published: 2020

NARROW

The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomas

Assessment of Tumor Metabolic Volume (TMV) As a Predictor of Outcomes in Patients with Relapsed/Refractory Primary Mediastinal B-Cell Lymphoma (PMBCL)

Outcomes of Sequenced Therapy in Mantle Cell Lymphoma in Patients Treated with First-Line Autologous Stem Cell Transplantation and Second-Line BTK Inhibitor

Survival and Therapeutic Outcomes in T-Cell Prolymphocytic Leukemia (T-PLL): A Collaborative Multi-Center Study Cohort

Single Cell Atlas of Cutaneous T Cell Lymphomas Reveals XPO1 Dependency

The Fusion Landscape of Anaplastic Large Cell Lymphoma: An L.L.M.P.P. Study

CDK9 Is a Vulnerability in GATA-3 Driven and MCL-1 Independent T-Cell Lymphomas

Asparaginase Treatment Patterns, Toxicity, and Outcomes Among Patients with Extranodal NK/T-Cell Lymphoma: A North American Multicenter Retrospective Cohort Study

Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma

Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition

Xpo-1 Antagonism Transcriptionally Reprograms and Is a Therapeutic Vulnerability in GATA-3 Driven T-Cell Lymphomas

Xpo-1 Antagonism Impairs CSF-1R Expression and Depletes Lymphoma-Associated Macrophages in T-Cell Lymphomas

Pre-Clinical Activity of Navitoclax in TCR-Driven and Non-ALCL Mature T-Cell Lymphomas

A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Getting ALK inhibitors SHPshape

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only